Compass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD

Reuters

2025/08/08

Compass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD

Compass Pathways plc recently held an investor presentation highlighting their ongoing efforts in transforming mental health care. The company is currently conducting a Phase 3 Treatment-Resistant Depression $(TRD.UK)$ program with their lead product candidate, COMP360 psilocybin treatment. The first pivotal trial (COMP005) has achieved its 6-week primary endpoint, while data from the second pivotal trial (COMP006) is expected in the second half of 2026. Additionally, their Phase 2 TRD program has been published in The New England Journal of Medicine, and positive top-line data from a Phase 2 PTSD study was reported in the second quarter of 2024, with a late-stage clinical study in development. As of June 30, 2025, Compass Pathways reported a cash position of $222 million. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on August 06, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557421567"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557421567\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557421567?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 00:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557421567","market":"us","top_or_hot":-1,"title":"Compass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Pathways plc recently held an investor presentation highlighting their ongoing efforts in transforming mental health care. The company is currently conducting a Phase 3 Treatment-Resistant Depression <a href=\"https://laohu8.com/S/TRD.UK\">$(TRD.UK)$</a> program with their lead product candidate, COMP360 psilocybin treatment. The first pivotal trial (COMP005) has achieved its 6-week primary endpoint, while data from the second pivotal trial (COMP006) is expected in the second half of 2026. Additionally, their Phase 2 TRD program has been published in The <a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine, and positive top-line data from a Phase 2 PTSD study was reported in the second quarter of 2024, with a late-stage clinical study in development. As of June 30, 2025, Compass Pathways reported a cash position of $222 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on August 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-08 00:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Pathways plc recently held an investor presentation highlighting their ongoing efforts in transforming mental health care. The company is currently conducting a Phase 3 Treatment-Resistant Depression <a href=\"https://laohu8.com/S/TRD.UK\">$(TRD.UK)$</a> program with their lead product candidate, COMP360 psilocybin treatment. The first pivotal trial (COMP005) has achieved its 6-week primary endpoint, while data from the second pivotal trial (COMP006) is expected in the second half of 2026. Additionally, their Phase 2 TRD program has been published in The <a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine, and positive top-line data from a Phase 2 PTSD study was reported in the second quarter of 2024, with a late-stage clinical study in development. As of June 30, 2025, Compass Pathways reported a cash position of $222 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on August 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDL9k4dPP:1","article_id":"2557421567","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557421567","pubTimestamp":1754582837,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Compass Pathways plc recently held an investor presentation highlighting their ongoing efforts in transforming mental health care. The company is currently conducting a Phase 3 Treatment-Resistant Depression  program with their lead product candidate, COMP360 psilocybin treatment. The first pivotal trial  has achieved its 6-week primary endpoint, while data from the second pivotal trial  is expected in the second half of 2026. Additionally, their Phase 2 TRD program has been published in The New England Journal of Medicine, and positive top-line data from a Phase 2 PTSD study was reported in the second quarter of 2024, with a late-stage clinical study in development. As of June 30, 2025, Compass Pathways reported a cash position of $222 million. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CMPS":"COMPASS Pathways plc"},"translate_title":"Compass Pathways plc发布关于通过TRD和PTSD创新疗法转变心理卫生保健的演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPS":0.9},"content_text":"Compass Pathways plc Releases Presentation on Transforming Mental Health Care with Innovative Treatments for TRD and PTSD\n    \n\n        Compass Pathways plc recently held an investor presentation highlighting their ongoing efforts in transforming mental health care. The company is currently conducting a Phase 3 Treatment-Resistant Depression $(TRD.UK)$ program with their lead product candidate, COMP360 psilocybin treatment. The first pivotal trial (COMP005) has achieved its 6-week primary endpoint, while data from the second pivotal trial (COMP006) is expected in the second half of 2026. Additionally, their Phase 2 TRD program has been published in The New England Journal of Medicine, and positive top-line data from a Phase 2 PTSD study was reported in the second quarter of 2024, with a late-stage clinical study in development. As of June 30, 2025, Compass Pathways reported a cash position of $222 million. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on August 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}